Thanks LPP for taking the initiative to go after the cons bashing CYDY. Karmas a B and they will get theirs. Hopefully it's not a family member who could benefit from one of the many treatments of Leronlimab. I'm hoping that our product is able to reduce effects of CV, and believe the value would come from the exposure and not in value from treatment with this virus. Awareness is what we need and our time is coming!